Publications

Advancing scientific exchange

Discover Camurus’ publications and engagement at conducted and upcoming international medical conferences and events.

Filter by indicationsAcromegalyOpioid dependenceFilter by year

Impact of baseline factors on opioid negative urine tests among patients with opioid use disorder receiving weekly/monthly extended-release injectable buprenorphine (CAM2038) vs daily sublingual buprenorphine/naloxone

Comer S.D. et al.

CPDD 2025

Poster

CAM2029, an Octreotide Subcutaneous FluidCrystal® Depot, Provides Biochemical Control of Acromegaly and Improves Patient Reported Outcomes: Interim Results From the Phase 3 ACROINNOVA 2 Trial

Silverstein J.M. et al.

AACE 2025

Poster

Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly

Glatard A. et al.

Clinal Pharmacokinetics, 2025 May 26. Online ahead of print.

Article

CAM2029 Octreotide Subcutaneous Depot Maintains Control of IGF-I and Symptoms of Acromegaly Across the 4-Week Dosing Interval and During Intervals Greater Than 28 Days: Data from the ACROINNOVA 1 Trial

Gadelha M.R. et al.

ENDO 2025

Poster

Improved Patient‑Reported Outcomes with CAM2029 Treatment, an Octreotide Subcutaneous Depot, in Patients with Acromegaly Previously on Standard-of-Care Injectable Somatostatin Receptor Ligands: Final Analysis of the Core Part of the ACROINNOVA 2 Phase 3 Trial

Ferone D. et al.

ENDO 2025

Poster

CAM2029, an Octreotide Subcutaneous Depot, Provides Long-Term and Sustained Biochemical Control of Acromegaly: Final Analysis of the Core Part of the ACROINNOVA 2 Phase 3 Trial

Spencer-Segal J.L et al.

ENDO 2025

Poster

CAM2029 octreotide subcutaneous depot provides stable control of IGF-I and improves key symptoms throughout a 4-week post-dose interval: analysis from the ACROINNOVA 1 trial

Gadelha M.R. et al.

ESPE/ESE 2025

Poster

CAM2029, a self-administered subcutaneous octreotide depot, improved PROs and symptoms in patients with acromegaly in the ACROINNOVA 2 Phase 3 trial: final analysis of the core phase results

Ferone D. et al.

ESPE/ESE 2025

Poster

Results from the core phase of the open-label, Phase 3 ACROINNOVA 2 trial: CAM2029, a subcutaneous octreotide depot, achieves sustained, long-term biochemical control in acromegaly

Spencer-Segal J.L. et al.

ESPE/ESE 2025

Poster

Publications

Advancing scientific exchange

Impact of baseline factors on opioid negative urine tests among patients with opioid use disorder receiving weekly/monthly extended-release injectable buprenorphine (CAM2038) vs daily sublingual buprenorphine/naloxone

CAM2029, an Octreotide Subcutaneous FluidCrystal® Depot, Provides Biochemical Control of Acromegaly and Improves Patient Reported Outcomes: Interim Results From the Phase 3 ACROINNOVA 2 Trial

Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly

CAM2029 Octreotide Subcutaneous Depot Maintains Control of IGF-I and Symptoms of Acromegaly Across the 4-Week Dosing Interval and During Intervals Greater Than 28 Days: Data from the ACROINNOVA 1 Trial

Improved Patient‑Reported Outcomes with CAM2029 Treatment, an Octreotide Subcutaneous Depot, in Patients with Acromegaly Previously on Standard-of-Care Injectable Somatostatin Receptor Ligands: Final Analysis of the Core Part of the ACROINNOVA 2 Phase 3 Trial

CAM2029, an Octreotide Subcutaneous Depot, Provides Long-Term and Sustained Biochemical Control of Acromegaly: Final Analysis of the Core Part of the ACROINNOVA 2 Phase 3 Trial

CAM2029 octreotide subcutaneous depot provides stable control of IGF-I and improves key symptoms throughout a 4-week post-dose interval: analysis from the ACROINNOVA 1 trial

CAM2029, a self-administered subcutaneous octreotide depot, improved PROs and symptoms in patients with acromegaly in the ACROINNOVA 2 Phase 3 trial: final analysis of the core phase results

Results from the core phase of the open-label, Phase 3 ACROINNOVA 2 trial: CAM2029, a subcutaneous octreotide depot, achieves sustained, long-term biochemical control in acromegaly

Quicklinks

Corporate Site

Address

Publications

Advancing scientific exchange

Impact of baseline factors on opioid negative urine tests among patients with opioid use disorder receiving weekly/monthly extended-release injectable buprenorphine (CAM2038) vs daily sublingual buprenorphine/naloxone

CAM2029, an Octreotide Subcutaneous FluidCrystal® Depot, Provides Biochemical Control of Acromegaly and Improves Patient Reported Outcomes: Interim Results From the Phase 3 ACROINNOVA 2 Trial

Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly

CAM2029 Octreotide Subcutaneous Depot Maintains Control of IGF-I and Symptoms of Acromegaly Across the 4-Week Dosing Interval and During Intervals Greater Than 28 Days: Data from the ACROINNOVA 1 Trial

Improved Patient‑Reported Outcomes with CAM2029 Treatment, an Octreotide Subcutaneous Depot, in Patients with Acromegaly Previously on Standard-of-Care Injectable Somatostatin Receptor Ligands: Final Analysis of the Core Part of the ACROINNOVA 2 Phase 3 Trial

CAM2029, an Octreotide Subcutaneous Depot, Provides Long-Term and Sustained Biochemical Control of Acromegaly: Final Analysis of the Core Part of the ACROINNOVA 2 Phase 3 Trial

CAM2029 octreotide subcutaneous depot provides stable control of IGF-I and improves key symptoms throughout a 4-week post-dose interval: analysis from the ACROINNOVA 1 trial

CAM2029, a self-administered subcutaneous octreotide depot, improved PROs and symptoms in patients with acromegaly in the ACROINNOVA 2 Phase 3 trial: final analysis of the core phase results

Results from the core phase of the open-label, Phase 3 ACROINNOVA 2 trial: CAM2029, a subcutaneous octreotide depot, achieves sustained, long-term biochemical control in acromegaly

Log in

Don’t have an account?

Quicklinks

Corporate Site

Address